Epidemiology, demographics, and pathophysiology of acute spinal cord injury
- PMID: 11805601
- DOI: 10.1097/00007632-200112151-00002
Epidemiology, demographics, and pathophysiology of acute spinal cord injury
Abstract
Spinal cord injury occurs through various countries throughout the world with an annual incidence of 15 to 40 cases per million, with the causes of these injuries ranging from motor vehicle accidents and community violence to recreational activities and workplace-related injuries. Survival has improved along with a greater appreciation of patterns of presentation, survival, and complications. Despite much work having been done, the only treatment to date known to ameliorate neurologic dysfunction that occurs at or below the level of neurologic injury has been intravenous methylprednisolone therapy. Much research over the past 30 to 40 years has focused on elucidating the mechanisms of spinal cord injury, with the complex pathophysiologic processes slowly being unraveled. With a greater understanding of both primary and secondary mechanisms of injury, the roles of calcium, free radicals, sodium, excitatory amino acids, vascular mediators, and apoptosis have been elucidated. This review examines the epidemiology, demographics, and pathophysiology of acute spinal cord injury.
Similar articles
-
Pathophysiology and pharmacologic treatment of acute spinal cord injury.Spine J. 2004 Jul-Aug;4(4):451-64. doi: 10.1016/j.spinee.2003.07.007. Spine J. 2004. PMID: 15246307 Review.
-
Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.JAMA. 1997 May 28;277(20):1597-604. JAMA. 1997. PMID: 9168289 Clinical Trial.
-
Pharmacological interventions for acute spinal cord injury.Cochrane Database Syst Rev. 2000;(2):CD001046. doi: 10.1002/14651858.CD001046. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(3):CD001046. doi: 10.1002/14651858.CD001046 PMID: 10796741 Updated. Review.
-
Neuroprotection after spinal cord injury: state of the science.SCI Nurs. 1997 Mar;14(1):8-18. SCI Nurs. 1997. PMID: 9165951 Review.
-
Use of methylprednisolone as an adjunct in the management of patients with penetrating spinal cord injury: outcome analysis.Neurosurgery. 1996 Dec;39(6):1141-8; discussion 1148-9. doi: 10.1097/00006123-199612000-00014. Neurosurgery. 1996. PMID: 8938768 Clinical Trial.
Cited by
-
Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury.J Neurotrauma. 2013 Mar 15;30(6):441-52. doi: 10.1089/neu.2012.2622. Epub 2013 Mar 21. J Neurotrauma. 2013. PMID: 23517137 Free PMC article.
-
Effects of tumor necrosis factor alpha blocker adalimumab in experimental spinal cord injury.J Korean Neurosurg Soc. 2015 Feb;57(2):73-6. doi: 10.3340/jkns.2015.57.2.73. Epub 2015 Feb 26. J Korean Neurosurg Soc. 2015. PMID: 25733985 Free PMC article.
-
The potential for cellular therapy combined with growth factors in spinal cord injury.Stem Cells Int. 2012;2012:826754. doi: 10.1155/2012/826754. Epub 2012 Oct 3. Stem Cells Int. 2012. PMID: 23091499 Free PMC article.
-
The association between economic indicators and the incidence of tetraplegia from traumatic spinal cord injury in Taiwan.BMC Neurol. 2021 Mar 17;21(1):117. doi: 10.1186/s12883-021-02141-8. BMC Neurol. 2021. PMID: 33731028 Free PMC article.
-
The effect of ATLS/PHTLS spinal motion restriction protocol on the incidence of spinal cord injury, a nationwide database study.Eur Spine J. 2024 Sep;33(9):3637-3644. doi: 10.1007/s00586-024-08421-4. Epub 2024 Aug 9. Eur Spine J. 2024. PMID: 39122846
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
